Boston Scientific beats Q3 expectations, raises 2025 guidance amid strong performance in key franchises like WATCHMAN and FARAPULSE/pulsed-field ablation.
Thermo Fisher raises 2025 revenue guidance and lifts annual profit outlook after strong Q3 results.
Boston Scientific beats Q3 expectations, raises 2025 guidance amid strong performance in key franchises like WATCHMAN and FARAPULSE/pulsed-field ablation.
Thermo Fisher raises 2025 revenue guidance and lifts annual profit outlook after strong Q3 results.